KEVIN CHARLES GORMAN - 13 Feb 2024 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)

Role
Chief Executive Officer, Director
Signature
/s/ Darin Lippoldt, Attorney-in-Fact
Issuer symbol
NBIX
Transactions as of
13 Feb 2024
Transactions value $
$0
Form type
4
Filing time
14 Feb 2024, 17:17:01 UTC
Previous filing
08 Feb 2024
Next filing
17 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NBIX Common Stock Options Exercise $100K +2.78K +0.55% $35.99 510K 13 Feb 2024 Direct F1
transaction NBIX Common Stock Options Exercise $100K +2.31K +0.45% $43.24 512K 13 Feb 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NBIX Incentive Stock Option Options Exercise -$100K -2.78K -100% $35.99 0 13 Feb 2024 Common Stock 2.78K $35.99 Direct F3
transaction NBIX Incentive Stock Option Options Exercise -$100K -2.31K -100% $43.24 0 13 Feb 2024 Common Stock 2.31K $43.24 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock.
F2 491,365 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power.
F3 The option was granted February 5, 2016 and vested in 48 equal monthly installments beginning March 5, 2016.
F4 The option was granted February 6, 2017 and vested in 48 equal monthly installments beginning March 6, 2017.